Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Carbone M., Kanodia S., Chao A. et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 2016;11:1246–1262.
  2. Linton A., Vardy J., Clarkeet S. et al. The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. J Critical Rev Oncol 2012;84(2):200–212.
  3. Asbestos (Chrysotile, Amosite, Crocidolite, Tremolite, Actinolite, and Anthophyllite). Arsenic, Metals, Fibres, and Dusts 100 C. Geneva: WHO Press, 2012. Pр. 219–310.
  4. Brown L.M., Howard R.A., Travis L.B. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:2741–2742.
  5. Teta M.J., Lau E., Sceurman B.K. et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007;109:1432–1438.
  6. Dogan A.U., Baris Y.I., Dogan M. et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006;66,10:5063–5068.
  7. Bocchetta M.I., Resta Di, Powers A. et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos co-carcinogenesis. Proc Natl Acad Sci USA 2000;97:10214–10219.
  8. Teta M.J., Mink P.J., Lau E. et al. US mesothelioma patterns 1973–2002: indicators of change and insights into background rates. Eur J Cancer Prev 2008;17:525–534.
  9. Музалевский П.Н., Шойхет Я.Н., Лазарев А.Ф. и др. Мезотелиома. Распространенность и модифицирующие факторы (литературный обзор). Сибирский онкологический журнал 2007;2(22):77–83.
  10. Surveillance, Epidemiology and End Results (SEER)/Cancer Statistics Review 1973–1999. Anon (2003). Available at: http://seer.cancer.gov/csr/1973–1999/overview/overview21pdf.
  11. Robinson B.M. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491–496.
  12. Hodgson J.T., McElvenny D.M., Darnton A.J. et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587–593.
  13. Лазарев А.Ф., Григорук О.Г., Базулина Л.М. и др. Мезотелиома плевры: этиология, заболеваемость, диагностика, лечение, выживаемость. Российский онкологический журнал 2013;5:15–20.
  14. Горбунова В.А. Характеристика пациентов с мезотелиомой плевры в Российской Федерации. Value in Health. 2014;17(7):323–686.
  15. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Available at: http://apps.who.int/classifications/icd10/browse/2016/en.
  16. Rusch V.W.,Chansky K., Kindler H.L. et al. The IASLC Malignant Pleural Mesothelioma Staging Project: proposals for the M descriptors and for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J. Thorac Oncol, 2016, in press.
  17. Amin M.B., Edge S.B., Greene F.L. et al. AJCC (American Joint Committee on Cancer). Cancer Staging Manual. 8th edn. Chicago: Springer, 2017.
  18. Finn R.S., Brims F.J.H., Gandhi A. et al. Postmortem Findings of Malignant Pleural Mesothelioma: A Two-Center Study of 318 Patients. Chest 2012;142(5):1267–1273.
  19. Howard A Gutman. Lung cancer and mesothelioma. Book.Copyright. 2011;2:183-184
  20. Tural Onur et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicator in malignant mesothelioma? Therap and Clin Risk Management. 2016;12:651-656
  21. Rochet N. et al. The role of complete blood cell count in prognosis – watch this space! Oncol and Hematol rew. 2012;8(1):76-82
  22. Van Zandwijk N. et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J. Thorac Dis. 2013; 5:E254-307
  23. Koksal D. et al. Thromboembolic events in malignant pleural mesothelioma //Clinical and Applied Thrombosis/Hemostasis. – 2016. – Т. 22. – №. 4. – С. 390-394
  24. Takamori S. et al. The C-reactive protein/albumin ratio is a novel significant prognostic factor in patients with malignant pleural mesothelioma: a retrospective multi-institutional study //Annals of surgical oncology. – 2018. – Т. 25. – №. 6. – С. 1555-1563
  25. Harris E. J. A. et al. Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery //Journal of Thoracic Oncology. – 2019. – Т. 14. – №. 2. – С. 288-293
  26. Boudville N et al. Mesothelin and kidney function analysis of relationship and implications for mesothelioma screening. Lung Cancer. 2011;73(3):320-4
  27. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190–8
  28. Cheng et al. Clinical significance of serum CA125 in diffuse malignant mesothelioma. SpringerPlus. 2016; 5:368.
  29. Creaney J. et al. Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma. Chest J. 2007; 132:1239-1246.
  30. Shalaby A.O. et al. A study of CA-125 in patient with pleural effusion. Egypt J Bronchol. 2015;9:283-6.
  31. Резников Ю.П. и коллеги. Оценка соотношения онкомаркеров в поиске первичного очага опухоли (к 50-летию открытия АФП как опухолевого маркера). Клиническая лабораторная диагностика. 2014; 2:15-19.
  32. Truong M.T., Viswanathan C., Godoy M.B. et al. Malignant Pleural Mesothelioma: Role of CT, MRI, and PET/CT in Staging Evaluation and Treatment Considerations. J Semin Roentgenol 2013;48(4):323–334.
  33. Kawashima A., Libshitz H. I. Malignant pleural mesothelioma: CT manifestations in 50 cases //AJR. American journal of roentgenology. – 1990. – Т. 155. – №. 5. – С. 965-969.
  34. Heelan R. T. et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging //AJR. American journal of roentgenology. – 1999. – Т. 172. – №. 4. – С. 1039-1047.
  35. Armato G. et al. Imaging in Pleural Mesothelioma: A Review of the 13th International Conference of the International Mesothelioma Interest Group. Lung Cancer. Author manuscript; available in PMC. 2017; 101: 48–58.
  36. Gossinger HD et al. Magnetic resonance imaging findings in a patient with pericardial mesothelioma. Arm Heart J. 1988;115(6):1321-22.
  37. Fazekas T. et al. Primary malignant pericardial mesothelioma. Orv Hetil. 1991;132 (48):2677-80.
  38. Collins D. et al. Patterns of metastases in malignant pleural mesothelioma in the modern ers: Redefining the spread of an old disease. J Clin Oncol. 2017;8556
  39. Kruse M., Sherry S., Paidpally V. et al. FDG PET/CT in the Management of Primary Pleural Tumors and Pleural Metastases. Am J Roentgenol 2013;201:215–226.
  40. Yildirim H. et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study //Journal of Thoracic Oncology. – 2009. – Т. 4. – №. 12. – С. 1480-1484.
  41. Kao SC et al. Accuracy of diagnostic biopsy of the histological subtype of the malignant pleural mesothelioma. J Thorac Oncol. 2011;6:602-605.
  42. Greillier L. Et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.Cancer 2007;110:2248-2252.
  43. Wald O. et al. Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma. J Vis Surg. 2016;2:129.
  44. Rice D. C. et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma //The Annals of thoracic surgery. – 2005. – Т. 80. – №. 6. – С. 1988-1993.
  45. Travis W.D., Colby T.V., Corrin B. et al. (WHO). Histological typing of lung and pleural tumour. Berlin: Springer, 1999. ISBN: 13978-3-540-65219-9.
  46. Flores RM et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620-626
  47. Spaggiari L. et al. Extapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg. 2014;97:1859-65
  48. Flores RM et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (SEER) population. J Thorac Oncol. 2010;5:1649-54
  49. Treasure T. et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patient with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study. Lancet Oncol. 2011;12:763-772
  50. Rusch V.W., Piantadosi S., Holmes E.C. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A lung cancer study group trial. J Thorac Cardiovasc Surg 1991;102(1):1– 9.
  51. Trousse D.S., Avaro J.P., D’Journo X.B. et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg 2009;36(4):759–763.
  52. Rintoul R.C., Ritchie A.J., Edwards J.G. et al. MesoVATS Collaborators: Efficacy and cost of video- assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384:1118–1127.
  53. Walker S., Bibby A.C., Maskell N.A. Current best practice in the evaluation and management of malignant pleural effusions. Ther Adv Respir Dis. 2017;11(2):105–114
  54. Girardi L. et al. Periocardiocentesis and intrapericardial sclerosis: effective therapy for malignant pericardial effusions. The Annals of Thoracic Surgery. 1997;64(5):1422-1428
  55. Catot S. et al. Primary malignant pericardial methotelioma. ResearchGate. 2012;4:39-48
  56. Vigneswaran WT. & Stefanacci PR. Pericardial mesothelioma. Current Treatment Options in Oncology. 2000;1(4):299-302
  57. Anderson TM et al. Pericardial catheter sclerosis versus surgical procedures for pericardial effusions in cancer patients. Journal of Cardiovascular Surgery (Torino).2001;42 (3):415-9
  58. Tsang TS et al. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clinic Proceedings. 2000;75(3):248-53
  59. Plas E et al: Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer. 1998;83:2437-2446.
  60. Gupta N.P., Kumar R. Malignant gonadal mesothelioma // Curr. Treat. Opt. Oncol. 2002. V. 3 (5). P. 363-367
  61. Plas E., Riedl C.R., Pflüger H. Malignant mesothelioma of the tunica vaginalis testis. Review of the literature and assessment of prognostic parameters // Cancer. 1998. V. 83. P. 2437-2446.
  62. Огнерубов Н.А., Огнерубова И.Н. Мезотелиома оболочек яичка. Весник ТГУ. 2013;18(4):1326-29
  63. Bang J.H. et al. Surgical experience of pericardial mesothelioma presenting as constrictive pericarditis. J of Cardiology Cases.2010;2:e96-98.
  64. Bassem et al.Unusual Presentation of a Primary Pericardial Malignant Mesothelioma: Constrictive Pericarditis A Case Report and Review of the Literature. J Tumor Res. 2015; 1:1.
  65. Yan T.D. et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827-34.
  66. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
  67. Feldman AL, Libutti SK, Pingpank JF, et al: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy J Clin Oncol. 2003;21:4560–4567.
  68. Brigand C. et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: Results of a prospective study. Ann Surg Oncol. 2006;13:405–412.
  69. Yano H. et al. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009;35:980–985.
  70. Blackham A.U. et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: Mitomycin versus cisplatin. Ann Surg Oncol.2010;17:2720–2727.
  71. Baratti D. et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45–53.
  72. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol.2006;32:948–953.
  73. Helm JH, Miura JT, Glenn JA et al: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: A systematic review and meta- analysis. Ann Surg Oncol. 2015;22:1686–1693.
  74. Isik AF, Sanli M, Yilmaz M, et al. Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies. Respir Med. 2013;107:762–7.
  75. Gupta V et al. Hemithoracic radiation therapy after pleurectomy/decortications for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045-1052
  76. Gupta V et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol 2009;4:746-750
  77. Bolukbas M et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleuroectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011;71:75-81
  78. Hasani A et al. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in Western Australia. J Thorac Oncol 2009;4:1010-1016
  79. Rimner A., Zauderer M.G., Gomez D.R. et al. Phase II study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol 2016;34:2761–2768.
  80. Finkelstein S.E., Timmerman R., McBride W.H. et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011;439752:7.
  81. Rusch V.W., Rosenzweig K., Venkatraman E. et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788–795.
  82. Boutin C et al. Prevention of malignant seeding after invasive procedures in patients with malignant pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754- 758
  83. Ball DL et al. The treatment of malignant mesothelioma of pleura: review of a 5-years experience, with special reference to radiotherapy. Am J Clin Oncol 1999;13:4-9
  84. Chance WW et al. Hemithoracic intensity modulated radiation therapy after pleuroectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 2015;91:149-156
  85. Vogelzang N.J., Rusthoven J.J., Symanowski J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–2644.
  86. Castagneto B., Bota M., Aitini E. et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma. Ann Oncol 2008;19:370–373.
  87. Nowak A.K., Byrne M.J., Willianson R. et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491–496.
  88. Van Haarst J.M., Baas J., Manegold C.H. et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342–345.
  89. Van Meerbeeck JP et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999;85:2577-2282
  90. Zauderer M.G. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma / M.G. Zauderer, S.L. Kass, K. Woo et al. // Lung Cancer 2014;84:271-274
  91. Taylor P et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008;3:764-771
  92. Stebbing, J. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma / J. Stebbing, T. Powles, K. McPherson et al. // Lung Cancer. – 2009. – Vol. 63. – P. 94-97.
  93. Muers MF et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): multicentre randomized trial. Lancet 2008;371:1685-1894
  94. Vogelzang N.J., Herdon J., Clamon G.H. et al. Paclitaxel (Taxol) for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9234). Proc. Am.Soc. Clin. Oncol. 1994:405.
  95. Ogura O. et al. A case of malignant peritoneal mesothelioma successfully treated with carboplatin and paclitaxel.Gan To Kagaku Ryoho. 2006;33(7):1001-4.
  96. Schutte W, Blankenburg T, Lauerwald K et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003;4: 294–297.
  97. Ardizzoni A, Rosso R, Salvati F et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1999; 67: 2984–2987.
  98. Dowell J.E., Dunphy F.R., Taub R.N. et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012;77:567–571.
  99. Kindler H.L., Karrison T.G., Gandara D.R. et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012;30:2509–2515.Zalcman G et al.
  100. Zalcman G et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomized controlled, open-label, Phase 3 trail. Lancet 2016;387:1405-1414
  101. Ceresoli GL et al. Phase II study of pemetrexed and carboplatin plus bevasizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013;109:552-558.
  102. Popat S, Cunoni-Fontecedro A, Polydoropoulou V, et al. A multicenter randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM)—results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Presented at: 2019 ESMO Congress; September 27 to October 1, 2019. Abstract LBA91.
  103. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non- randomised, open-label, phase 1b trial. Lancet Oncol 2017;18:623-30.
  104. Disselhorst M, Harms E, Van Tinteren H, et al. Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study. J Thorac Oncol. 2012;11:S1746.
  105. Zalcman G et al. Second or 3rd line nivolumab (Nivo) versus nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial [abstract]. Ann Oncol 2017;28 Abstract LBA58_PR
  106. Quispel-Janssen J, Zago G, Schouten R, et al. A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies. J Thorac Oncol. 2017;12:S292-3.
  107. Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT- 1501 MAPS2 randomized phase II trial. J Clin Oncol. 2017;35
  108. Bolukbas S., Manegold C., Eberlein M. Safety and efficacy of trimodality therapy in patients undergoing extrapleural pneumonectomy. Lung Cancer 2011;71:75–81.
  109. Hasegava S. et al. Evoluation of surgical approach in malignant pleural mesothelioma. 2016. Abst. MS09.06. iMig2016.org.
  110. Kushalnagar P., Engelman A., Sadler G. Deaf patient-provider communication and lung cancer screening: Health Information National Trends survey in American Sign Language (HINTS-ASL). Patient Educ Couns 2018 Jul;101(7):1232–1239.
  111. Bovolato P, Casadio C, Billè A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9:390-6.
  112. Kepenekian V. et al. RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer. 2016;65:69-79.
  113. Sharkey A.J. et al. Induction or adjuvant chemotherapy for radical multimodality therapy. SHC. 2018;2(7):1-8.
  114. Sharkey A.J. et al. How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? Lung Cancer. 2016;100:5-13.
  115. Janssen S.M., Abbink J.J., Lindeboom R., Vliet Vlieland T.P. Outcomes of Pulmonary Rehabilitation After Treatment for Non-Small Cell Lung Cancer Stages I to IIIa: AN OBSERVATIONAL STUDY. J Cardiopulm Rehabil Prev. 2017;37(1):65–71.
  116. Muzi J.L., Look R.M., Turner C., Gardiner S.K., Wagie T., Douglas J., Sorenson L., Evans L., Kirchner S., Dashkoff C., Garrett K., Johnson N. Low-level laser therapy for chemotherapy- induced peripheral neuropathy. Journal of Clinical Oncology. 2012;30(15):9019.
  117. Ross M., Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs. 2017;21(2):226–233.
  118. Edwards J.G., Abrams K.R., Leverment J.N. et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:731–735.
  119. Lim John Wah et al. “Preventive measures to eliminate asbestos-related diseases in singapore.” Safety and health at work. 2011;2,3:201-9.
  120. Карпенко Т.Д., Козлов Н.А., Любченко Л.Н. и др. Анализ экспрессии белка PD-L1 в клетках злокачественной мезотелиомы плевры. Российский онкологический журнал. 2018;23(1):4– 9.
  121. Scherpereel A., Astoul P., Baas P. et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479–495.
  122. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. Ed. by C. MacLeod. New York: Columbia University Press. 1949:191–205.
  123. Бычков М.Б., Абдуллаев А.Г., Багрова С.Г., Барболина Т.Д., Борисова Т.Н., Владимирова Л.Ю.и соавт. Практические рекомендации по лекарственному лечению мезотелиомы плевры, брюшины и других локализаций. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2019 (том 9). С. 55-67.
  124. Gregorc V. et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial //The Lancet Oncology. – 2018. – Т. 19. – №. 6. – С. 799-811.
  125. Краткие методические указания по учету и диспансеризации больных с предраковыми и злокачественными новообразованиями. [Электронный ресурс] Режим доступа//URL: http://www.oncology.ru/service/organization/table1.htm. Дата последнего обращения: 2 апреля 2020 г.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу